Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 3, 2011

Premium

Title: RNA Interference-Mediated Inhibition of Telomerase Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,897,752

Filed: July 9, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating telomerase gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of telomerase gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules ... used to modulate the expression of telomerase genes, such as telomerase template RNA or a telomerase protein.”


Title: RNA Interference-Mediated Inhibition of XIAP Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,897,753

Filed: Sept. 5, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules … and methods used to modulate the expression of XIAP genes.”


Title: siRNA Targeting Ras-Related Nucleic Protein RAN

Patent Number: 7,897,754

Filed: Sept. 11, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”


Title: RNA Interference-Mediated Inhibition of Platelet-Derived Endothelial Cell Growth Factor Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,897,755

Filed: Jan. 19, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules ... and methods used to modulate the expression of ECGF1 and/or ECGF1r genes.”


Title: RNA Interference-Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,897,756

Filed: Jan. 26, 2010

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules … and methods used to modulate the expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220, NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2.”


Title: RNA Interference-Mediated Inhibition of Protein Tyrosine Phosphatase-1B Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,897,757

Filed: Feb. 25, 2010

Lead Inventor: Leonid Beigelman, Sirna Therapeutics (Merck)

“This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the ... invention features small nucleic acid molecules … and methods used to modulate the expression of PTP-1B genes. Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes in a subject or organism, and for any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue, alone or in combination with other treatments or therapies.”


Title: Multi-Conjugate of siRNA and Preparing Method Thereof

Application Number: 20110044931

Filed: April 29, 2009

Inventor: Tae Gwan Park, Korea Advanced Institute of Science and Technology

The invention, the patent application's abstract states, “relates to a multi-conjugate of small interfering RNA and a [method of preparing] a multi-conjugate of siRNA prepared by direct binding of double-stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the ... invention is characterized by simple and efficient reaction and thereby the ... siRNA multi-conjugate ... has high molecular weight multiple times [greater than] the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene-delivery efficiency.”


Title: Transfection Results of Non-Viral Gene Delivery Systems by Influencing of the Innate Immune System

Application Number: 20110045001

Filed: March 27, 2009

Lead Inventor: Roland Klosel, Biontex Laboratories

“The innate immune system of eukaryotes is able to recognize foreign genetic material by means of Toll-like receptors and to initiate signal transduction cascades that trigger an antiviral state of cell populations by way of an interferon response,” the patent application's abstract states. “That antiviral state is also a barrier for non-viral gene delivery systems. If the signal transduction cascade is interrupted intracellularly or intercellularly, transfection efficiencies of non-viral gene delivery systems can be increased and undesirable changes in the expression profile can be avoided. Since RNA interference is to be attributed to the antiviral state, the RNAi machinery is likewise activated after activation of the innate immune system. In that way, knock-down efficiencies on transfection with siRNA can be increased.”


Title: Compositions Comprising Human EGFR-siRNA and Methods of Use

Application Number: 20110046067

Filed: June 20, 2008

Lead Inventor: Xiaodong Yang, Intradigm (Silence Therapeutics)

The invention provides “nucleic acid molecules that inhibit EGFR expression,” the patent application's abstract states. “Methods of using the nucleic acid molecules are also provided.”


Title: Methods and Compositions for Seamless Cloning of Nucleic Acid Molecules

Application Number: 20110046201

Filed: April 30, 2008

Lead Inventor: Jonathan Chesnut, Invitrogen (Life Technologies)

The invention “relates to cloning or subcloning one or more nucleic acid molecules comprising one or more type IIs restriction enzyme recognition sites,” the patent application's abstract states. The invention also “embodies cloning such nucleic acid molecules using recombinational cloning methods such as those employing recombination sites and recombination proteins … [and] relates to nucleic acid molecules, including RNA and iRNA ... expressed from host cells produced using the methods” of the invention.


Title: Double-Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation

Application Number: 20110046206

Filed: June 23, 2008

Lead Inventor: Balkrishen Bhat, Isis Pharmaceuticals

The invention comprises “double-stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified [to have] a selected motif,” according to the patent application's abstract. “The motifs are defined by positioning of differentially modified nucleosides wherein at least the sugar moieties are different. More particularly, the ... compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif, or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage.

“The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes,” the abstract adds. “In preferred embodiments, the compositions ... hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.”


Title: RNA-Induced Translational Silencing and Cellular Apoptosis

Application Number: 20110046209

Filed: May 1, 2009

Lead Inventor: Paul Anderson, Brigham and Women's Hospital

“The invention is directed to RNA molecules that can be used to inhibit protein synthesis and to induce cells to undergo apoptosis,” the patent application's abstract states. “It also includes pharmaceutical compositions containing the RNAs that can be used in treating or preventing tumors; abnormal dermatological growths and viral infections.”

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.